Seer (NASDAQ:SEER) Upgraded to “Strong-Buy” at TD Cowen

TD Cowen upgraded shares of Seer (NASDAQ:SEER) to a strong-buy rating in a research report sent to investors on Monday,Zacks.com reports.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

Seer Stock Performance

SEER stock traded down $0.01 on Monday, hitting $1.94. 80,971 shares of the company’s stock were exchanged, compared to its average volume of 301,113. Seer has a 12-month low of $1.65 and a 12-month high of $2.41. The firm has a 50 day moving average price of $1.82 and a two-hundred day moving average price of $1.94. The stock has a market cap of $109.17 million, a P/E ratio of -1.51 and a beta of 1.59.

Seer (NASDAQ:SEER) last announced its earnings results on Thursday, February 26th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.03. Seer had a negative return on equity of 26.04% and a negative net margin of 443.96%.The firm had revenue of $4.20 million for the quarter, compared to the consensus estimate of $4.60 million. Sell-side analysts expect that Seer will post -1.42 earnings per share for the current fiscal year.

Institutional Trading of Seer

Large investors have recently added to or reduced their stakes in the company. Occudo Quantitative Strategies LP purchased a new stake in Seer during the 2nd quarter valued at about $25,000. Marshall Wace LLP purchased a new stake in shares of Seer in the fourth quarter worth about $85,000. Quadrature Capital Ltd purchased a new stake in shares of Seer in the fourth quarter worth about $101,000. Barclays PLC boosted its stake in shares of Seer by 685.0% in the fourth quarter. Barclays PLC now owns 60,717 shares of the company’s stock worth $111,000 after buying an additional 52,982 shares during the last quarter. Finally, Corient Private Wealth LLC purchased a new stake in shares of Seer in the fourth quarter worth about $116,000. Hedge funds and other institutional investors own 75.20% of the company’s stock.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.